Invitrogen Takes a Step Further Into Dx Reagent Market With Caltag Buy | GenomeWeb

Continuing its shopping spree for new protein-related technologies — and gaining another foothold in the diagnostic reagents market — Invitrogen this week said it will pay $20 million in cash to acquire Caltag Laboratories, a California manufacturer of immunological reagents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.